Sakellariou‐Thompson et al89 recently noted that CD8+ TILs derived from pancreatic cancer tissue could be grown with the aid of a 4‐1BB agonist, suggesting the clinical feasibility of TIL adoptive cell therapy. This evidence concerns the gene CD8A and familial pancreatic carcinoma.